Cannabidiol and epilepsy: Rationale and therapeutic potential

Pharmacological Research

Volumn 107, Issue , 2016, Pages 85-92

  Leo, Antonio ^a   Russo, Emilio ^a   Elia, Maurizio ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Cannabidiol; Clinical evidence; Epilepsy; Preclinical studies; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CLOBAZAM; DRONABINOL;

ANTICONVULSANT ACTIVITY; CANNABIS USE; CONTROLLED CLINICAL TRIAL (TOPIC); CONVULSION; DECREASED APPETITE; DISEASE EXACERBATION; DROWSINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG RESISTANT EPILEPSY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LENNOX GASTAUT SYNDROME; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; SOMNOLENCE; STURGE WEBER SYNDROME; ANIMAL;

ANIMALS; ANTICONVULSANTS; CANNABIDIOL; EPILEPSY; HUMANS;

EID: 84961614087     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.03.005     Document Type: Review

References (90)

1. E.M. Goldberg, and D.A. Coulter Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction Nat. Rev. Neurosci. 14 2013 337 349
2. A. Pitkanen, and K. Lukasiuk Mechanisms of epileptogenesis and potential treatment targets Lancet Neurol. 10 2011 173 186
3. H.S. White, and W. Loscher Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies Neurotherapeutics 11 2014 373 384
4. R. Citraro, A. Leo, P. De Fazio, G. De Sarro, and E. Russo Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the wag/rij rat model of absence epilepsy Br. J. Pharmacol. 172 2015 3177 3188
5. A. Pitkanen, and J. Engel Jr. Past and present definitions of epileptogenesis and its biomarkers Neurotherapeutics 11 2014 231 241
6. R. Citraro, A. Leo, R. Marra, G. De Sarro, and E. Russo Antiepileptogenic effects of the selective cox-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in wag/rij rats Brain Res. Bull. 113 2015 1 7
7. R. Citraro, A. Leo, A. Constanti, E. Russo, and G. De Sarro Mtor activity as a new therapeutic strategy in epilepsy Pharmacol. Res. 2016 (in press)
8. P. Kwan, and M.J. Brodie Refractory epilepsy: mechanisms and solutions Expert Rev. Neurother. 6 2006 397 406
9. P. Perucca, and F.G. Gilliam Adverse effects of antiepileptic drugs Lancet Neurol. 11 2012 792 802
10. A.M. Kanner, J.J. Barry, F. Gilliam, B. Hermann, and K.J. Meador Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia 53 2012 1104 1108
11. R. Citraro, A. Leo, P. de Fazio, G. De Sarro, and E. Russo Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behavior in the wag/rij rat model of absence epilepsy Br. J. Pharmacol. 172 2015 3177 3188
12. R. Citraro, A. Leo, R. Aiello, M. Pugliese, E. Russo, and G. De Sarro Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats Neurotherapeutics 12 2015 250 262
13. D. Friedman, and O. Devinsky Cannabinoids in the treatment of epilepsy N. Engl. J. Med. 373 2015 1048 1058
14. E.C. Rosenberg, R.W. Tsien, B.J. Whalley, and O. Devinsky Cannabinoids and epilepsy Neurotherapeutics 12 2015 747 768
15. O. Devinsky, M.R. Cilio, H. Cross, J. Fernandez-Ruiz, J. French, C. Hill, R. Katz, V. Di Marzo, D. Jutras-Aswad, W.G. Notcutt, J. Martinez-Orgado, P.J. Robson, B.G. Rohrback, E. Thiele, B. Whalley, and D. Friedman Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders Epilepsia 55 2014 791 802
16. I. Katona Cannabis and endocannabinoid signaling in epilepsy Handb. Exp. Pharmacol. 231 2015 285 316
17. K. Detyniecki, and L.J. Hirsch Cannabidiol for epilepsy: trying to see through the haze Lancet Neurol. 2016
18. D. Gloss, and B. Vickrey Cannabinoids for epilepsy Cochrane Database Syst. Rev. 3 2014 CD009270
19. M.C. Paolino, A. Ferretti, L. Papetti, M.P. Villa, and P. Parisi Cannabidiol as potential treatment in refractory pediatric epilepsy Expert Rev. Neurother. 2015 1 5
20. J. Killestein Cannabinoids in the treatment of epilepsy N. Engl. J. Med. 374 2016 94
21. J.P. Szaflarski, and E. Martina Bebin Cannabis, cannabidiol, and epilepsy - from receptors to clinical response Epilepsy Behav. 41 2014 277 282
22. A.L. Geffrey, S.F. Pollack, P.L. Bruno, and E.A. Thiele Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy Epilepsia 56 2015 1246 1251
23. C. Ibeas Bih, T. Chen, A.V. Nunn, M. Bazelot, M. Dallas, and B.J. Whalley Molecular targets of cannabidiol in neurological disorders Neurotherapeutics 12 2015 699 730
24. A. Thomas, G.L. Baillie, A.M. Phillips, R.K. Razdan, R.A. Ross, and R.G. Pertwee Cannabidiol displays unexpectedly high potency as an antagonist of cb1 and cb2 receptor agonists in vitro Br. J. Pharmacol. 150 2007 613 623
25. J.M. McPartland, M. Duncan, V. Di Marzo, and R.G. Pertwee Are cannabidiol and delta(9) - tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review Br. J. Pharmacol. 172 2015 737 753
26. R.G. Pertwee The diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin Br. J. Pharmacol. 153 2008 199 215
27. E.B. Russo, A. Burnett, B. Hall, and K.K. Parker Agonistic properties of cannabidiol at 5-ht1a receptors Neurochem. Res. 30 2005 1037 1043
28. M.R. Pazos, N. Mohammed, H. Lafuente, M. Santos, E. Martinez-Pinilla, E. Moreno, E. Valdizan, J. Romero, A. Pazos, R. Franco, C.J. Hillard, F.J. Alvarez, and J. Martinez-Orgado Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5ht(1a) and cb2 receptors Neuropharmacology 71 2013 282 291
29. L. De Petrocellis, A. Ligresti, A.S. Moriello, M. Allara, T. Bisogno, S. Petrosino, C.G. Stott, and V. Di Marzo Effects of cannabinoids and cannabinoid-enriched cannabis extracts on trp channels and endocannabinoid metabolic enzymes Br. J. Pharmacol. 163 2011 1479 1494
30. F.A. Iannotti, C.L. Hill, A. Leo, A. Alhusaini, C. Soubrane, E. Mazzarella, E. Russo, B.J. Whalley, V. Di Marzo, and G.J. Stephens Nonpsychotropic plant cannabinoids, cannabidivarin (cbdv) and cannabidiol (cbd), activate and desensitize transient receptor potential vanilloid 1 (trpv1) channels in vitro: potential for the treatment of neuronal hyperexcitability ACS Chem. Neurosci. 5 2014 1131 1141
31. P. Pandolfo, V. Silveirinha, A. dos Santos-Rodrigues, L. Venance, C. Ledent, R.N. Takahashi, R.A. Cunha, and A. Kofalvi Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum Eur. J. Pharmacol. 655 2011 38 45
32. S.P. Banerjee, S.H. Snyder, and R. Mechoulam Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes J. Pharmacol. Exp. Ther. 194 1975 74 81
33. W. Xiong, T. Cui, K. Cheng, F. Yang, S.R. Chen, D. Willenbring, Y. Guan, H.L. Pan, K. Ren, Y. Xu, and L. Zhang Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors J. Exp. Med. 209 2012 1121 1134
34. J. Ahrens, R. Demir, M. Leuwer, J. de la Roche, K. Krampfl, N. Foadi, M. Karst, and G. Haeseler The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function Pharmacology 83 2009 217 222
35. R.G. dos Santos, J.E. Hallak, J.P. Leite, A.W. Zuardi, and J.A. Crippa Phytocannabinoids and epilepsy J. Clin. Pharm. Ther. 40 2015 135 143
36. N.A. Jones, S.E. Glyn, S. Akiyama, T.D. Hill, A.J. Hill, S.E. Weston, M.D. Burnett, Y. Yamasaki, G.J. Stephens, B.J. Whalley, and C.M. Williams Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures Seizure 21 2012 344 352
37. A.C. Campos, M.V. Fogaca, A.B. Sonego, and F.S. Guimaraes Cannabidiol, neuroprotection and neuropsychiatric disorders Pharmacol. Res. 2016 (in press)
38. D. Cheng, A.S. Spiro, A.M. Jenner, B. Garner, and T. Karl Long-term cannabidiol treatment prevents the development of social recognition memory deficits in alzheimer's disease transgenic mice J. Alzheimers Dis. 42 2014 1383 1396
39. E.M. Blessing, M.M. Steenkamp, J. Manzanares, and C.R. Marmar Cannabidiol as a potential treatment for anxiety disorders Neurotherapeutics 12 2015 825 836
40. V. Micale, V. Di Marzo, A. Sulcova, C.T. Wotjak, and F. Drago Endocannabinoid system and mood disorders: priming a target for new therapies Pharmacol. Ther. 138 2013 18 37
41. M.W. Manseau, and D.C. Goff Cannabinoids and schizophrenia: risks and therapeutic potential Neurotherapeutics 12 2015 816 824
42. A.R. Brooks-Kayal, K.G. Bath, A.T. Berg, A.S. Galanopoulou, G.L. Holmes, F.E. Jensen, A.M. Kanner, T.J. O'Brien, V.H. Whittemore, M.R. Winawer, M. Patel, and H.E. Scharfman Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy Epilepsia 54 Suppl. 4 2013 44 60
43. R. Linge, L. Jimenez-Sanchez, L. Campa, F. Pilar-Cuellar, R. Vidal, A. Pazos, A. Adell, and A. Diaz Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-ht/glutamate neurotransmission: role of 5-ht receptors Neuropharmacology 103 2015 16 26
44. A.J. Hill, C.M. Williams, B.J. Whalley, and G.J. Stephens Phytocannabinoids as novel therapeutic agents in cns disorders Pharmacol. Ther. 133 2012 79 97
45. M. Bialer, S.I. Johannessen, R.H. Levy, E. Perucca, T. Tomson, and H.S. White Progress report on new antiepileptic drugs: a summary of the twelfth eilat conference (eilat xii) Epilepsy Res. 111 2015 85 141
46. T.D. Hill, M.G. Cascio, B. Romano, M. Duncan, R.G. Pertwee, C.M. Williams, B.J. Whalley, and A.J. Hill Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a cb1 receptor-independent mechanism Br. J. Pharmacol. 170 2013 679 692
47. C. Scuderi, D.D. Filippis, T. Iuvone, A. Blasio, A. Steardo, and G. Esposito Cannabidiol in medicine: a review of its therapeutic potential in cns disorders Phytother. Res. 23 2009 597 602
48. P. Consroe, M.A. Benedito, J.R. Leite, E.A. Carlini, and R. Mechoulam Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice Eur. J. Pharmacol. 83 1982 293 298
49. B.K. Colasanti, C. Lindamood 3rd, and C.R. Craig Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats Pharmacol. Biochem. Behav. 16 1982 573 578
50. R. Karler, and S.A. Turkanis The cannabinoids as potential antiepileptics J. Clin. Pharmacol. 21 1981 437S 448S
51. E.A. Carlini, J.R. Leite, M. Tannhauser, and A.C. Berardi Letter: cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents J. Pharm. Pharmacol. 25 1973 664 665
52. P. Consroe, and A. Wolkin Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats J. Pharmacol. Exp. Ther. 201 1977 26 32
53. O. Zendulka, G. Dovrtelova, K. Noskova, M. Turjap, A. Sulcova, L. Hanus, and J. Jurica Cannabinoids and cytochrome p450 interactions Curr. Drug Metab. 17 2016 206 226
54. N.A. Jones, A.J. Hill, I. Smith, S.A. Bevan, C.M. Williams, B.J. Whalley, and G.J. Stephens Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo J. Pharmacol. Exp. Ther. 332 2010 569 577
55. Z. Shirazi-zand, L. Ahmad-Molaei, F. Motamedi, and N. Naderi The role of potassium bk channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice Epilepsy Behav. 28 2013 1 7
56. A. Leo, R. Citraro, A. Constanti, G. De Sarro, and E. Russo Are big potassium-type ca-activated potassium channels a viable target for the treatment of epilepsy? Expert Opin. Ther. Targets 2015 1 16
57. A. Vezzani Epilepsy and inflammation in the brain: overview and pathophysiology Epilepsy Curr. 14 2014 3 7
58. O. Devinsky, A. Vezzani, S. Najjar, N.C. De Lanerolle, and M.A. Rogawski Glia and epilepsy: excitability and inflammation Trends Neurosci. 36 2013 174 184
59. K. Mao, C. You, D. Lei, and H. Zhang High dosage of cannabidiol (cbd) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect Int. J. Clin. Exp. Med. 8 2015 8820 8827
60. M. Hosseinzadeh, S. Nikseresht, F. Khodagholi, N. Naderi, and N. Maghsoudi Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure J. Mol. Neurosci. 2016 (in press)
61. F.J. Alvarez, H. Lafuente, M.C. Rey-Santano, V.E. Mielgo, E. Gastiasoro, M. Rueda, R.G. Pertwee, A.I. Castillo, J. Romero, and J. Martinez-Orgado Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets Pediatr. Res. 64 2008 653 658
62. C.J. Hillard Role of cannabinoids and endocannabinoids in cerebral ischemia Curr. Pharm. Des. 14 2008 2347 2361
63. A.J. Hill, M.S. Mercier, T.D. Hill, S.E. Glyn, N.A. Jones, Y. Yamasaki, T. Futamura, M. Duncan, C.G. Stott, G.J. Stephens, C.M. Williams, and B.J. Whalley Cannabidivarin is anticonvulsant in mouse and rat Br. J. Pharmacol. 167 2012 1629 1642
64. N. Amada, Y. Yamasaki, C.M. Williams, and B.J. Whalley Cannabidivarin (cbdv) suppresses pentylenetetrazole (ptz)-induced increases in epilepsy-related gene expression PeerJ 1 2013 e214
65. D.S. Reddy, and V. Golub The pharmacological basis of cannabis therapy for epilepsy J. Pharmacol. Exp. Ther. 357 2016 45 55
66. M.S. Castaneto, A. Wohlfarth, N.A. Desrosiers, R.L. Hartman, D.A. Gorelick, and M.A. Huestis Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices Drug Metab. Rev. 47 2015 124 174
67. M.A. Huestis Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol Handb. Exp. Pharmacol. 2005 657 690
68. I.J. McGilveray Pharmacokinetics of cannabinoids Pain Res. Manag. 10 Suppl. A 2005 15A 22A
69. O. Zendulka, G. Dovrtelova, K. Noskova, M. Turjap, A. Sulcova, L. Hanus, and J. Jurica Cannabinoids and cytochrome p450 interactions Curr. Drug Metab. 17 2016 206 226
70. H.H. Ramsey, and J.P. Davis Anti-epileptic action of marijuana- active substances Fed. Proc. 8 1949 167
71. P.F. Consroe, G.C. Wood, and H. Buchsbaum Anticonvulsant nature of marihuana smoking JAMA 234 1975 306 307
72. J.M. Ellison, E. Gelwan, and J. Ogletree Complex partial seizure symptoms affected by marijuana abuse J. Clin. Psychiatry 51 1990 439 440
73. M.H. Keeler, and C.B. Reifler Grand mal convulsions subsequent to marijuana use. Case report Dis. Nerv. Syst. 28 1967 474 475
74. R. Lorenz On the application of cannabis in paediatrics and epileptology Neuro Endocrinol. Lett. 25 2004 40 44
75. M. Hegde, C. Santos-Sanchez, C.P. Hess, A.A. Kabir, and P.A. Garcia Seizure exacerbation in two patients with focal epilepsy following marijuana cessation Epilepsy Behav. 25 2012 563 566
76. D. Saade, and C. Joshi Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report Pediatr. Neurol. 52 2015 544 547
77. D.W. Gross, J. Hamm, N.L. Ashworth, and D. Quigley Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center Neurology 62 2004 2095 2097
78. B.E. Porter, and C. Jacobson Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy Epilepsy Behav. 29 2013 574 577
79. M. Hamerle, L. Ghaeni, A. Kowski, F. Weissinger, and M. Holtkamp Cannabis and other illicit drug use in epilepsy patients Eur. J. Neurol. 21 2014 167 170
80. S.A. Hussain, R. Zhou, C. Jacobson, J. Weng, E. Cheng, J. Lay, P. Hung, J.T. Lerner, and R. Sankar Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and lennox-gastaut syndrome Epilepsy Behav. 47 2015 138 141
81. C.A. Press, K.G. Knupp, and K.E. Chapman Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy Epilepsy Behav. 45 2015 49 52
82. G.W. Mathern, L. Beninsig, and A. Nehlig Fewer specialists support using medical marijuana and cbd in treating epilepsy patients compared with other medical professionals and patients: result of epilepsia's survey Epilepsia 56 2015 1 6
83. M. Tzadok, S. Uliel-Siboni, I. Linder, U. Kramer, O. Epstein, S. Menascu, A. Nissenkorn, O.B. Yosef, E. Hyman, D. Granot, M. Dor, T. Lerman-Sagie, and B. Ben-Zeev Cbd-enriched medical cannabis for intractable pediatric epilepsy: the current israeli experience Seizure 35 2016 41 44
84. J.M. Cunha, E.A. Carlini, A.E. Pereira, O.L. Ramos, C. Pimentel, R. Gagliardi, W.L. Sanvito, N. Lander, and R. Mechoulam Chronic administration of cannabidiol to healthy volunteers and epileptic patients Pharmacology 21 1980 175 185
85. F.R. Ames, and S. Cridland Anticonvulsant effect of cannabidiol S. Afr. Med. J. 69 1986 14
86. R. Mechoulam, and E.A. Carlini Toward drugs derived from cannabis Naturwissenschaften 65 1978 174 179
87. S.M.B. Trembly Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids International Conference on Cannabis and Cannabinoids 1990 July 8-11; Kolympari, Crete.: International Association for Cannabinoid Medicines 1990
88. B.S. Koppel, J.C. Brust, T. Fife, J. Bronstein, S. Youssof, G. Gronseth, and D. Gloss Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development subcommittee of the American academy of neurology Neurology 82 2014 1556 1563
89. D. Ekstein Issues and promise in clinical studies of botanicals with anticonvulsant potential Epilepsy Behav. 52 2015 329 332
90. O. Devinsky, E. Marsh, D. Friedman, E. Thiele, L. Laux, J. Sullivan, I. Miller, R. Flamini, A. Wilfong, F. Filloux, M. Wong, N. Tilton, P. Bruno, J. Bluvstein, J. Hedlund, R. Kamens, J. Maclean, S. Nangia, N.S. Singhal, C.A. Wilson, A. Patel, and M.R. Cilio Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial Lancet Neurol. 15 2016 270 278